Christina Y. Weng, MD, MBA, FASRS, highlights findings showing statin use reduced PVR risk by 25% in a propensity-matched ...
Roivant Sciences announced positive results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease, or PH-ILD, with the study ...
A preclinical study by Mass Eye and Ear investigators showed that a novel mRNA-based therapy may be able to prevent blindness and scarring from proliferative vitreoretinopathy (PVR) following a ...
Please provide your email address to receive an email when new articles are posted on . Statin use reduced proliferative vitreoretinopathy risk by 47% and complex reoperation rate by 48%. All dosing ...
PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, ...
Please provide your email address to receive an email when new articles are posted on . Patients with epiretinal membrane after proliferative vitreoretinopathy repair may benefit from early peeling, ...
JERUSALEM and HOUSTON, March 7, 2022 /PRNewswire/ -- Nectin Therapeutics Ltd., (Nectin) a biotechnology company developing novel targeted immunotherapies that address resistance to approved immune ...
DUBLIN, April 27, 2020 /PRNewswire/ -- The "Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This pipeline guide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results